Brokerages forecast that Clovis Oncology (NASDAQ:CLVS) will announce sales of $35.50 million for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Clovis Oncology’s earnings. The highest sales estimate is $36.97 million and the lowest is $33.12 million. Clovis Oncology posted sales of $23.76 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 49.4%. The firm is expected to report its next earnings report on Wednesday, August 7th.

According to Zacks, analysts expect that Clovis Oncology will report full year sales of $149.31 million for the current financial year, with estimates ranging from $145.00 million to $154.03 million. For the next financial year, analysts anticipate that the company will report sales of $233.63 million, with estimates ranging from $199.70 million to $252.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Clovis Oncology.

Clovis Oncology (NASDAQ:CLVS) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.63) EPS for the quarter, topping the consensus estimate of ($1.80) by $0.17. The business had revenue of $33.12 million for the quarter, compared to the consensus estimate of $32.10 million. Clovis Oncology had a negative return on equity of 196.39% and a negative net margin of 342.54%. Clovis Oncology’s revenue was up 78.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.38) EPS.

Several research analysts have recently commented on CLVS shares. SunTrust Banks boosted their target price on Clovis Oncology to $35.00 and gave the stock a “buy” rating in a report on Wednesday, February 27th. BidaskClub raised Clovis Oncology from a “sell” rating to a “hold” rating in a report on Friday, March 1st. Zacks Investment Research downgraded Clovis Oncology from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. ValuEngine raised Clovis Oncology from a “sell” rating to a “hold” rating in a report on Monday, April 1st. Finally, JPMorgan Chase & Co. reissued a “hold” rating and issued a $27.00 target price on shares of Clovis Oncology in a report on Wednesday, February 27th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $27.44.

In related news, insider Lindsey Rolfe sold 1,729 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $26.13, for a total value of $45,178.77. Following the completion of the transaction, the insider now owns 20,953 shares in the company, valued at approximately $547,501.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 2,453 shares of company stock valued at $56,038 in the last 90 days. 8.30% of the stock is currently owned by corporate insiders.

Several institutional investors have recently modified their holdings of the business. Pearl River Capital LLC purchased a new position in Clovis Oncology in the first quarter valued at about $40,000. NumerixS Investment Technologies Inc purchased a new position in Clovis Oncology in the first quarter valued at about $62,000. Ladenburg Thalmann Financial Services Inc. boosted its stake in Clovis Oncology by 93.4% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,146 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 1,519 shares during the last quarter. Great West Life Assurance Co. Can raised its position in shares of Clovis Oncology by 54.8% in the fourth quarter. Great West Life Assurance Co. Can now owns 7,034 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 2,489 shares during the period. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new stake in shares of Clovis Oncology in the first quarter valued at approximately $192,000. Institutional investors own 93.28% of the company’s stock.

Shares of CLVS traded down $0.42 on Friday, hitting $12.95. The company’s stock had a trading volume of 1,286,678 shares, compared to its average volume of 1,680,285. The company has a market capitalization of $708.74 million, a P/E ratio of -1.83 and a beta of 1.99. The company has a debt-to-equity ratio of 8.04, a current ratio of 4.39 and a quick ratio of 4.15. Clovis Oncology has a fifty-two week low of $11.50 and a fifty-two week high of $50.00.

About Clovis Oncology

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Further Reading: Growth and Income Funds

Get a free copy of the Zacks research report on Clovis Oncology (CLVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.